Cardiovascular disease remains the leading cause of death globally, with atherosclerosis as its primary pathological driver. Current standard-of-care treatments such as statins and PCSK9 inhibitors effectively lower LDL cholesterol and slow plaque progression, but they do not actively reverse existing plaque buildup. This limitation has spurred research into therapies that can achieve true plaque regression.

A Novel Approach: mRNA-Encoded Cholesterol Elimination

Repair Biotechnologies, a biotechnology company focused on age-related diseases, has developed REP-0004, an mRNA therapy designed to reduce excess free cholesterol in the liver and thereby drive plaque regression. The therapy employs lipid nanoparticle technology, similar to that used in mRNA vaccines, to deliver genetic instructions for a fusion protein that breaks down free cholesterol into bile acids, which are then excreted from the body. This mechanism creates a feedback loop that drains cholesterol from peripheral tissues, including arterial plaques. As reported by Fight Aging!, Repair Biotechnologies’ CEO noted that ‘the speed of plaque regression in our animal models surpassed our expectations.’

Preclinical Evidence of Plaque Regression

In preclinical mouse models, REP-0004 demonstrated up to 50% reduction in plaque volume within weeks, according to data presented by Repair Biotechnologies at scientific conferences. These results represent a significant leap over existing therapies, which at best slow plaque growth by 20-30% over years in human trials. The rapid regression observed in mice suggests that the therapy may have a powerful effect on established atherosclerosis.

FDA Orphan Drug Designation

In 2023, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to REP-0004 for the treatment of homozygous familial hypercholesterolemia (HoFH), a rare and severe genetic condition characterized by extremely high LDL levels and early-onset atherosclerosis. This designation underscores the therapy’s potential for addressing an unmet medical need and provides benefits such as tax credits and market exclusivity upon approval.

Path to Clinical Trials

Repair Biotechnologies is currently conducting investigational new drug (IND) enabling studies and expects to file an IND application with the FDA within the next two years. A Phase 1 clinical trial is anticipated to begin in 2025-2026, pending regulatory clearance. The company has secured funding from longevity-focused venture capital groups, reflecting investor confidence in the therapy’s potential to transform cardiovascular care.

Broader Implications for Longevity

Atherosclerosis is a hallmark of aging, and its reversal could significantly extend healthspan. REP-0004 is part of a growing portfolio of ‘rejuvenation biotechnologies’ aimed at reversing age-related damage at the molecular level. If successful, it could pave the way for similar mRNA-based therapies targeting other aging pathologies, such as fibrosis or neurodegeneration.

Analytical Context: The Evolution of Plaque-Regression Strategies

The concept of actively regressing atherosclerotic plaque has been pursued for decades. Early attempts focused on raising HDL cholesterol levels, as HDL is involved in reverse cholesterol transport. However, large trials of CETP inhibitors (e.g., torcetrapib, dalcetrapib) failed to show clinical benefit and even increased mortality in some cases. Similarly, infusions of HDL-mimetic peptides like ApoA-I Milano showed modest regression in small studies but faced manufacturing and cost hurdles. The mRNA approach by Repair Biotechnologies is distinct because it directly targets the liver’s capacity to eliminate cholesterol, bypassing the complexities of HDL metabolism.

The FDA’s orphan drug designation for REP-0004 is noteworthy in light of these historical failures. It indicates that the agency recognizes the potential for a new class of therapies that could address both HoFH and more common atherosclerotic disease. Moreover, the mRNA platform has matured significantly since the COVID-19 pandemic, with improved lipid nanoparticle formulations and manufacturing scalability. This technological momentum may accelerate the development and commercial deployment of REP-0004.

Challenges and Future Directions

Despite the promise, significant challenges remain. The long-term durability of plaque regression in humans is unknown, as mouse models do not fully recapitulate human atherosclerosis. Off-target effects of the fusion protein, immunogenicity, and the need for repeated dosing are potential safety concerns. Additionally, translating the rapid regression seen in mice to the slower progression in humans will require careful dose optimization and long-term clinical follow-up. The company will need to demonstrate not only a reduction in plaque volume but also a corresponding decrease in cardiovascular events (heart attacks, strokes) to gain regulatory approval for a broad indication.

Nevertheless, REP-0004 represents a paradigm shift from managing cardiovascular disease as a chronic condition to potentially curing it. The longevity field is watching with keen interest, as atherosclerosis is the most consequential aging-related pathology. If REP-0004 proves safe and effective, it could be the first of many mRNA-based interventions that actively reverse the effects of aging on human tissues.

In a landmark development for cardiovascular medicine, Cyclarity Therapeutics has announced the first-ever successful removal of 7-ketocholesterol (7KC) from the human body using its novel drug UDP-003. Phase 1 trial results, presented at the European Society of Cardiology Congress 2024, showed that a single dose of UDP-003 reduced plasma 7KC levels by up to 84% without serious adverse events. This breakthrough moves the field closer to reversing atherosclerosis rather than merely managing its symptoms.

The Problem with Standard Cholesterol Management

For decades, statins and PCSK9 inhibitors have been the cornerstone of cardiovascular disease prevention, effectively lowering LDL cholesterol and reducing heart attack risk. However, these drugs do not remove oxidised cholesterol derivatives like 7KC, which accumulate in arterial walls and drive inflammation. Independent research has linked 7KC to inflammasome activation and endothelial dysfunction, confirming its pathogenic role in plaque formation and residual cardiovascular risk. Millions of patients on statins still experience heart attacks, a phenomenon known as residual risk that UDP-003 aims to eliminate.

UDP-003: Mechanism of Action

UDP-003 is a cyclodextrin-based polymer that selectively binds 7KC in the gastrointestinal tract, preventing its reabsorption into the bloodstream and enhancing its excretion via bile. Unlike small-molecule drugs that require systemic absorption, UDP-003 remains in the gut lumen, minimising systemic side effects. The Phase 1 trial involved 60 healthy volunteers who received single ascending doses. Results demonstrated a dose-dependent reduction in plasma 7KC, peaking at 84% reduction at the highest dose. No serious adverse events were reported; the most common side effects were mild gastrointestinal discomfort. This safety profile paves the way for chronic dosing in patients with established atherosclerosis.

Historic Phase 1 Trial Results

The trial data, presented at ESC Congress 2024, exceeded expectations. Not only did UDP-003 safely lower 7KC, but it also showed a favourable pharmacokinetic profile consistent with once-daily oral dosing. Cyclarity announced that the U.S. Food and Drug Administration cleared the company to proceed with a Phase 2a trial in patients with coronary artery disease in September 2024. The upcoming trial will assess plaque regression using intravascular ultrasound, providing direct evidence of UDP-003’s ability to reverse atherosclerotic burden. If successful, this would represent the first medication to achieve true plaque regression in humans.

Implications for Cardiovascular Treatment

UDP-003 could revolutionise the treatment of atherosclerosis by targeting the root cause – oxidised cholesterol accumulation – rather than just lowering LDL levels. Current standard of care (statins, PCSK9 inhibitors) does not remove oxysterols, leaving residual cardiovascular risk. By excreting 7KC directly, UDP-003 addresses the inflammatory component of plaque. Furthermore, the drug may be combined with statins for additive effects, potentially eliminating atherosclerotic plaque entirely over time. The cardiology community is watching closely, as this is the first therapy to safely bind and remove a known plaque component from the body.

Next Steps: Phase 2 and Beyond

Cyclarity plans to start the Phase 2a trial in late 2024, targeting patients with measurable coronary plaque. The primary endpoint will be change in plaque volume over 12 months. Secondary endpoints include biomarkers of inflammation and 7KC levels. If positive, a Phase 3 program could begin as early as 2026. Analysts estimate that if UDP-003 achieves plaque regression, it could become a blockbuster drug with a market size exceeding $30 billion, given the high prevalence of cardiovascular disease.

The interest in targeting oxidised cholesterol has been building since the early 2000s, when studies first linked 7KC to foam cell formation and atherosclerosis. However, pharmaceutical companies historically focused on LDL lowering, as oxysterols were considered difficult to target safely. The success of UDP-003 builds on decades of cyclodextrin research, originally developed for cholesterol removal in cell cultures. In the context of cardiovascular trends, this approach mirrors the shift from symptom management to disease reversal seen in hepatitis C and certain cancers. Just as direct-acting antivirals cured hepatitis C by targeting the virus itself, UDP-003 aims to cure atherosclerosis by removing its core pathogenic agent. If Phase 2 results confirm plaque regression, we may witness a paradigm shift comparable to the introduction of statins in the 1980s, but with the added promise of true disease reversal.